Form 4: Avidity Director Sells Shares, Options in Novartis Merger

Avidity Biosciences Director Edward M. Kaye disposed of common stock and stock options as part of the previously announced merger with Novartis AG.

Summary

• Edward M. Kaye, a Director of Avidity Biosciences, Inc., disposed of 6,692 shares of common stock on February 27, 2026.
• The disposition also included several tranches of stock options, totaling 103,378 options, with exercise prices ranging from $0.42 to $39.96.
• These transactions occurred as a direct result of the Agreement and Plan of Merger, dated October 25, 2025, between Avidity Biosciences, Inc. and Novartis AG.
• The common stock was disposed of pursuant to the terms of the Merger Agreement.
• The stock options were disposed of in exchange for a cash payment equal to the merger consideration of $72.00 per share minus the respective exercise price of each option.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for the reporting person and Avidity shareholders, as it confirms the successful execution of a merger at a specified premium, indicating a favorable exit for equity holders.

Positives

• The reporting person realized a cash payment for their stock options, indicating a profitable exit for in-the-money options.
• The merger consideration of $72.00 per share represents a specific, favorable valuation for Avidity Biosciences, Inc. equity holders.

Negatives

• The disposition of all shares and options means the reporting person no longer holds direct beneficial ownership in Avidity Biosciences, Inc.
• Avidity Biosciences, Inc. will cease to be an independent publicly traded entity following the merger.

Risks

• No specific risks are mentioned in this Form 4 filing, as it reports a completed transaction related to a merger.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it reports a past transaction related to a merger.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that the acquisition of Avidity Biosciences by Novartis AG, as evidenced by this insider transaction, reflects a broader trend of consolidation within the biotechnology and pharmaceutical sectors. Larger pharmaceutical companies often acquire innovative biotech firms to bolster their pipelines and gain access to novel therapeutic platforms, such as Avidity's RNA-based therapeutics. This specific transaction indicates a successful exit for Avidity's shareholders and management, validating its technology and development efforts.

Comparison to Industry Standards

• StockSavvy.ai observes that the merger consideration of $72.00 per share for Avidity Biosciences, Inc. would be evaluated against recent biotech acquisitions. For instance, comparable deals might include Pfizer's acquisition of Seagen for $43 billion ($229 per share) in 2023, or Merck's acquisition of Prometheus Biosciences for $10.8 billion ($200 per share) in 2023.
• While the per-share price varies significantly based on company size, pipeline stage, and market conditions, the premium paid over Avidity's pre-merger trading price would be a key indicator of the deal's attractiveness.
• The cash payment for in-the-money options is standard practice in such transactions, ensuring all equity holders benefit from the acquisition.

Related Party Transactions

• The transaction is a disposition of securities by a director as part of a corporate merger, which is a standard corporate event rather than a related party transaction in the typical sense of preferential dealings.

Stakeholder Impact

• Shareholders: Existing shareholders of Avidity Biosciences, Inc. would have received the merger consideration of $72.00 per share, representing a liquidity event and a specific valuation for their investment.
• Employees: Employees holding stock options would have received cash payments for their in-the-money options, similar to the reporting person. The merger could lead to integration efforts impacting employment.
• Customers/Suppliers: The merger with Novartis AG could potentially impact future relationships, but this filing does not provide specific details.

Next Steps

• Completion of the merger between Avidity Biosciences, Inc. and Novartis AG, if not already finalized.
• Integration of Avidity Biosciences' assets and operations into Novartis AG.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Common Stock, Director, Beneficial Ownership